Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRATO phase 2b study of PF-06651600 and PF-06700841 in moderate to severe ulcerative colitis
NL-OMON48602Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing PF-06651600, PF-06700841 and Placebo (3 arms). Primary endpoint: Total Mayo score at Week 8. Planned start Jul 2017; status: withdrawn.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON48602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48602.